Request Your Free Trend Report Now:

"The Latest Developments in Oncology Research"

Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the pas

Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.

INCLUDED IN THIS TRENDLINE

• FDA panel backs broader use of CAR-T therapy for multiple myeloma
• Pfizer, looking for a jumpstart, leans into cancer drug research
• AbbVie joins ADC dealmaking with $10B ImmunoGen buyout

Offered Free by: BioPharma Dive and EVERSANA
See All Resources from: BioPharma Dive and EVERSANA